Novo Nordisk pitted a brand new weight-loss drug in opposition to Eli Lilly — and misplaced
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.